Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CytomX Therapeutics Q1 2024 GAAP EPS $0.17 Beats $(0.06) Estimate, Sales $41.463M Beat $21.434M Estimate

Author: Benzinga Newsdesk | May 08, 2024 05:01pm
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.06) by 383.33 percent. The company reported quarterly sales of $41.463 million which beat the analyst consensus estimate of $21.434 million by 93.44 percent. This is a 76.45 percent increase over sales of $23.499 million the same period last year.

Posted In: CTMX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist